BLENREP dosing regimen
Internet Explorer is no longer supported.
To provide you with the best possible experience, please switch to a supported browser e.g.
has been added to your basket
BLENREP offers an off-the-shelf B-cell maturation antigen (BCMA)- targeting monotherapy with a short infusion time for patients with triple-class refractory multiple myeloma
For GB healthcare professionals only.*
The recommended dose of BLENREP is:1
Treatment should be continued until disease progression or unacceptable toxicity.1
Clinical outcomes in a post-hoc analysis of patients who had prolonged dose delays (in which ≥3 treatment cycles were missed) in the 13-month follow up, after initially responding to BLENREP 2.5mg/kg (n=16/31)*3
*BLENREP is not commercially available in Northern Ireland.
BLENREP is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.1
AE, adverse event; BCMA, B cell maturation antigen; BCVA, best corrected visual acuity; SmPC, Summary of Product Characteristics.
▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.
© 2022 GSK Group of Companies or its licensor. Trademarks are the property of their respective owners.
February 2023 | PM-GB-BLM-WCNT-220006 (V2.0)